ABNewswire - Press Release Distribution Service

Tuesday, March 31, 2020

Acute Kidney Injury Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Acute Kidney Injury Market Insights, Epidemiology and Market Forecast-2030

DelveInsight's "Acute Kidney Injury (AKI) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Kidney Injury (AKI), historical and forecasted epidemiology as well as the Acute Kidney Injury (AKI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Kidney Injury (AKI) market report provides current treatment practices, emerging drugs, Acute Kidney Injury (AKI) market share of the individual therapies, current and forecasted Acute Kidney Injury (AKI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Acute Kidney Injury (AKI)is characterized by a rapid fall in glomerular filtration rate, clinically manifest as an abrupt and sustained rise in urea and creatinine. Life threatening consequences include volume overload, hyperkalaemia, and metabolic acidosis. As per the American Kidney Foundation organization, Acute Kidney Injury (AKI) was formerly called Acute Renal Failure.

Request for :- Free sample page

Epidemiology

The Acute Kidney Injury (AKI) epidemiology division provide insights about historical and current Acute Kidney Injury (AKI) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Report key facts:-

1. As per DelveInsight’s estimate, the total incident population of Acute Kidney Injury in seven major markets was 1,525,568 in 2017

2. Among the EU5 countries, Germany had the highest AKI diagnosed discharge cases with 82,902 cases followed by France and the United Kingdom, with diagnosed discharge cases of 67,282 and 66,196 respectively in 2017

3. AKI related hospitalization is less in Japan in comparison to other 7MM and reported incidence is 44,497 cases in 2017

Key company working on acute kidney injury are given below:-

1. Exponential Biotherapies

2. Alloksys

3. Angion Biomedical

Name of drugs covered are given below:-

1. EA-230

2. bRESCAP

3. ANG-3777 (BB3)

Table of content

1. Key Insights

2. Executive Summary of Acute Kidney Injury (AKI)

3. Competitive Intelligence Analysis for Acute Kidney Injury (AKI)

4. Acute Kidney Injury (AKI): Market Overview at a Glance

4.1. Acute Kidney Injury (AKI) Total Market Share (%) Distribution in 2017

4.2. Acute Kidney Injury (AKI) Total Market Share (%) Distribution in 2030

5. Acute Kidney Injury (AKI): Disease Background and Overview

6. Patient Journey

7. Acute Kidney Injury (AKI) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute Kidney Injury (AKI) Treatment and Management

8.2. Acute Kidney Injury (AKI) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Acute Kidney Injury (AKI) Treatment

11. Marketed Products

12. Emerging Therapies

13. Acute Kidney Injury (AKI): Seven Major Market Analysis

13.1. Key Findings

13.2. Acute Kidney Injury (AKI) Market Size in 7MM

13.3. Acute Kidney Injury (AKI) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute Kidney Injury (AKI)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Acute Kidney Injury (AKI) market
To understand the future market competition in the Acute Kidney Injury (AKI) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury (AKI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Acute Kidney Injury (AKI) market
To understand the future market competition in the Acute Kidney Injury (AKI) market

Related Reports:-

1. Acute Pancreatitis (AP) - Market Insight, Epidemiology and Market Forecast - 2028

2.Acute Unilateral Vestibulopathy (AUV) - Pipeline Insights, 2020

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Hallux Valgus Epidemiology Forecast to 2030

Hallux Valgus Epidemiology

DelveInsight's "Hallux Valgus Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted Hallux Valgus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

(Albany, US) DelveInsight launched a new report on Hallux Valgus Epidemiology Forecast to 2030

Some of the key facts of the report:-

The overall prevalence of definite radiographic Hallux Valgus was 29.8%.
Hallux valgus appears in at least 2% of children those who are aged 9 to 10 years, and almost half of adults, with a higher prevalence in women.
The estimates of Hallux Valgus prevalence were 23% in adults aged 18-65 years and 35.7% in older adults aged over 65 years.
Hallux Valgus more commonly affects females than males.

Request for sample pages:- https://www.delveinsight.com/sample-request/hallux-valgus-epidemiology-forecast

Scope of the Report

The Hallux Valgus report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Hallux Valgus Epidemiology Report and Model provide an overview of the risk factors and global trends of Hallux Valgus in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Hallux Valgus in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Hallux Valgus.
The report provides the segmentation of the Hallux Valgus epidemiology

Reasons to buy

The Hallux Valgus Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Hallux Valgus market
Quantify patient populations in the global Hallux Valgus market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hallux Valgus therapeutics in each of the markets covered
Understand the magnitude of Hallux Valgus population by its epidemiology
The Hallux Valgus Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Request for sample pages:- https://www.delveinsight.com/sample-request/hallux-valgus-epidemiology-forecast

Table of contents

1. Key Insights

2. Executive Summary of Hallux Valgus

3. Hallux Valgus: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Hallux Valgus Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Hallux Valgus Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Hallux Valgus Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Hallux Valgus Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Hallux Valgus Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Hallux Valgus Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Hallux Valgus Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Hallux Valgus Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Hallux Valgus Treatment and Management

6.2. Hallux Valgus Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Related reports :-

Hallux Valgus Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Hallux Valgus Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of disease and in depth understanding of disease epidemiology.

Hallux Valgus - Pipeline Insights, 2020

Hallux Valgus Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hallux Valgus market.

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email:Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Prurigo Nodularis Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2030

DelveInsight's "Prurigo Nodularis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Prurigo Nodularis market report provides current treatment practices, emerging drugs, Prurigo Nodularis market share of the individual therapies, current and forecasted Prurigo Nodularis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Prurigo Nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. PNs are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules”, which may occur as a sequel to chronic pruritus or neurotic excoriations. After establishing a perpetual itch-scratch cycle, lichenification of the skin may ensue, resulting in chronic dermatitis termed lichen simplex chronicus. Several lesions in different stages and sizes, may co-exist in patients with chronic pruritus, which were induced by chronic scratching.

Request for :- Prurigo Nodularis free sample page

Epidemiology

The Prurigo Nodularis epidemiology division provide insights about historical and current Prurigo Nodularis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Report Key facts:-

1. As per the study conducted by Mullins et al. (2019), a majority of patients with prurigo nodularis were present between ages 51 and 65, though several cases in other age groups have also been described. It seems to be more frequent and more intense in females than in males. It is seen as one of the clinical presentations of adult-onset atopic dermatitis. In HIV positive patients, prurigo nodularis is predictive of advanced immunosuppression.

2. As per DelveInsight’s analysis, it has been observed that most of the patients with Atopic PN account for ~75% of the total diagnosed PN cases, followed by Nonatopic PN (~25%) in the United States. In 2017, there were 116,653 Atopic PN and 38,884 Nonatopic PN patients

Major key companies working on Prurigo Nodularis that are given below:-

1. Sanofi Pharma Co.

2. Trevi Therapeutics

Name of drugs covered are given below:-

1. Dupilumab

2. Nalbuphine ER

Table of content

1. Key Insights

2. Executive Summary of Prurigo Nodularis

3. Competitive Intelligence Analysis for Prurigo Nodularis

4. Prurigo Nodularis: Market Overview at a Glance

4.1. Prurigo Nodularis Total Market Share (%) Distribution in 2017

4.2. Prurigo Nodularis Total Market Share (%) Distribution in 2030

5. Prurigo Nodularis: Disease Background and Overview

6. Patient Journey

7. Prurigo Nodularis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Prurigo Nodularis Treatment and Management

8.2. Prurigo Nodularis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Prurigo Nodularis Treatment

11. Marketed Products

12. Emerging Therapies

13. Prurigo Nodularis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Prurigo Nodularis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Prurigo Nodularis market
To understand the future market competition in the Prurigo Nodularis market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Prurigo Nodularis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Prurigo Nodularis market
To understand the future market competition in the Prurigo Nodularis market

Related Reports:-

1. Prurigo Nodularis - Epidemiology Forecast to 2030

2. Prurigo Nodularis - Pipeline Insights, 2020

Hallux Valgus Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Hallux Valgus Market Insights, Epidemiology and Market Forecast-2030

DelveInsight's "Hallux Valgus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hallux Valgus , historical and forecasted epidemiology as well as the Hallux Valgus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hallux Valgus market report provides current treatment practices, emerging drugs, Hallux Valgus market share of the individual therapies, current and forecasted Hallux Valgus market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hallux Valgus treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

According to the National Institute of Health (NIH), a bunion, known technically as hallux valgus, is a bony bump on the side of the foot at the base of the big toe. Bunions develop slowly as pressure on the joint at the base of the big toe causes the toe to move out of place, leaning inward toward the second toe. It is a progressive foot deformity in which the first metatarsophalangeal (MTP) joint is affected and is often accompanied by significant functional disability and foot pain. At a late stage, these changes lead to pain and functional deficit: i.e. impaired gait (lateral and posterior weight shift, late heel rise, decreased single-limb balance, and pronation deformity.

Request for :- free sample page

Epidemiology

The Hallux Valgus epidemiology division provide insights about historical and current Hallux Valgus patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Report Key facts:-

1. According to a study conducted by Nix et al. titled “Prevalence of hallux valgus in the general population: a systematic review and meta-analysis”, pooled prevalence estimates for Hallux Valgus were 23% in adults aged 18-65 years and 35.7% in elderly people aged over 65 years. However, the prevalence increased with age and was higher in females [30%] compared to males [13%].

2. The National health surveys in the United States have reported a prevalence of 0.9% across all age groups, while another survey in the United Kingdom reported a prevalence of 28.4% in adults. Research conducted in elderly populations has indicated prevalence rates as high as 74%. Individual studies have reported that Hallux Valgus is more common in female and elderly individuals than in males.

Table of content

1. Key Insights

2. Executive Summary of Hallux Valgus

3. Competitive Intelligence Analysis for Hallux Valgus

4. Hallux Valgus : Market Overview at a Glance

4.1. Hallux Valgus Total Market Share (%) Distribution in 2017

4.2. Hallux Valgus Total Market Share (%) Distribution in 2030

5. Hallux Valgus : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Hallux Valgus Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Hallux Valgus Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Hallux Valgus Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Hallux Valgus Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Hallux Valgus Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Hallux Valgus Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Hallux Valgus Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Hallux Valgus Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Hallux Valgus Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Hallux Valgus Treatment and Management

8.2. Hallux Valgus Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Hallux Valgus Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Hallux Valgus : Seven Major Market Analysis

13.1. Key Findings

13.2. Hallux Valgus Market Size in 7MM

13.3. Hallux Valgus Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Hallux Valgus Total Market Size in the United States

15.1.2. Hallux Valgus Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Hallux Valgus Total Market Size in Germany

15.3.2. Hallux Valgus Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Hallux Valgus Total Market Size in France

15.4.2. Hallux Valgus Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Hallux Valgus Total Market Size in Italy

15.5.2. Hallux Valgus Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Hallux Valgus Total Market Size in Spain

15.6.2. Hallux Valgus Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Hallux Valgus Total Market Size in the United Kingdom

15.7.2. Hallux Valgus Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Hallux Valgus Total Market Size in Japan

15.8.3. Hallux Valgus Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Hallux Valgus

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight.

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Hallux Valgus market
To understand the future market competition in the Hallux Valgus market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Hallux Valgus in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Hallux Valgus market
To understand the future market competition in the Hallux Valgus market.

Related Reports:-

1. Hallux Valgus - Epidemiology Forecast to 2030

2. Hallux Valgus - Pipeline Insights, 2020

Neuromyelitis Optica Pipeline Insight, 2020

(Albany, US) DelveInsight has launched a new report on Neuromyelitis Optica Market Insights, Epidemiology and Market Forecast-2030

"Neuromyelitis Optica Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neuromyelitis Optica market. A detailed picture of the Neuromyelitis Optica pipeline landscape is provided, which includes the disease overview and Neuromyelitis Optica treatment guidelines. The assessment part of the report embraces in-depth Neuromyelitis Optica commercial assessment and clinical assessment of the Neuromyelitis Optica pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuromyelitis Optica collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The characteristic symptoms of NMOSD are either optic neuritis or myelitis; either may occur as the first symptom. Optic neuritis is inflammation, of the optic nerve (optic neuritis) leading to pain inside the eye which rapidly is followed by loss of clear vision (acuity). Usually, only one eye is affected (unilateral) although both eyes may be involved simultaneously (bilateral). NMOSD may or may not be preceded by a prodromal upper respiratory infection.

Request for :- NMOSD free sample page

Neuromyelitis Optica of pipeline development activities

The report provides insights into:

All of the companies that are developing therapies for the treatment of Neuromyelitis Optica with aggregate therapies developed by each company for the same.
Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neuromyelitis Optica treatment.
Neuromyelitis Optica key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neuromyelitis Optica market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Neuromyelitis Optica Analytical Perspective by DelveInsight

In-depth Neuromyelitis Optica Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Neuromyelitis Optica Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Neuromyelitis Optica report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuromyelitis Optica across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of Neuromyelitis Optica therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed Neuromyelitis Optica research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neuromyelitis Optica.

Key companies working on NMOSD pipeline are given below:-

1. Roche Pharma Co.

2. Alexion Pharma

Name of drugs covered are given below:-

1. Satralizumab (SA237)

2. Soliris

Table of content

1. Report Introduction

2. Neuromyelitis Optica

3. Neuromyelitis Optica Current Treatment Patterns

3.1. Neuromyelitis Optica Treatment Guidelines

4. Neuromyelitis Optica - DelveInsight's Analytical Perspective

4.1.2.3. Neuromyelitis Optica Acquisition Analysis

5. Therapeutic Assessment

6. Neuromyelitis Optica Late Stage Products (Phase-III)

7. Neuromyelitis Optica Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neuromyelitis Optica Discontinued Products

13. Neuromyelitis Optica Product Profiles

14. Neuromyelitis Optica Key Companies

15. Neuromyelitis Optica Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Neuromyelitis Optica Unmet Needs

18. Neuromyelitis Optica Future Perspectives

19. Neuromyelitis Optica Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Related Reports:-

1. Neuromyelitis Optica Spectrum Disorder (NMOSD)- Market Insight, Epidemiology and Market Forecast -2030

2. Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast to 2030

Neuromyelitis Optica Spectrum Disorder Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight has launched a new report on Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology and Market Forecast-2030

DelveInsight's "Neuromyelitis Optica Spectrum Disorder (NMOSD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neuromyelitis Optica Spectrum Disorder (NMOSD) market report provides current treatment practices, emerging drugs, Neuromyelitis Optica Spectrum Disorder (NMOSD) market share of the individual therapies, current and forecasted Neuromyelitis Optica Spectrum Disorder (NMOSD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

According to National Multiple Sclerosis Society, Neuromyelitis optica (NMO) and NMO Spectrum Disorder (NMOSD), also known as Devic's disease, is an autoimmune disorder in which immune system cells and antibodies primarily attack the optic nerves and the spinal cord, but may also attack the brain. The damage to the optic nerves produces swelling and inflammation that cause pain and loss of vision; the damage to the spinal cord causes weakness or paralysis in the legs or arms, loss of sensation, and problems with bladder and bowel function. There are two forms of NMO/NMOSD: Relapsing and Monophasic.

Request for :- NMOSD free sample page

Epidemiology

The Neuromyelitis Optica Spectrum Disorder (NMOSD) epidemiology division provide insights about historical and current Neuromyelitis Optica Spectrum Disorder (NMOSD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Report Key facts :-

1. According to a study “Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan” 2017 conducted by Keiko Tanaka et al, the crude prevalence was 4.1/100,000 (95% confidence interval 2.2–6.9) for NMOSD in northern Japan, with a significantly higher number of female than male patients (female: male 12:2). The positivity for anti-aquaporin-4 antibody was 78.6%, and the mean age at onset was 45.2 years.

2. According to a study “Epidemiology of Neuromyelitis Optica in the World: A Systematic Review and Meta- Analysis” 2015, conducted by RezaVosoughiet al, the prevalence rate of 0.72/100000 (95% CI 0.31–1.42) and minimum combined average annual incidence rate of 0.08/100000 (95% CI 0.03–0.16) indicated that NMO is still an uncommon condition in UK adults.

key companies working on NMOSD that are given below:-

1. Chugai Pharmaceutical

2. Alexion Pharma

Name of drugs covered are given below:-

1. Satralizumab (SA237)

2. Soliris

Table of content

1. Key Insights

2. Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD)

3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder (NMOSD)

4. Neuromyelitis Optica Spectrum Disorder (NMOSD): Market Overview at a Glance

4.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Total Market Share (%) Distribution in 2017

4.2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Total Market Share (%) Distribution in 2030

5. Neuromyelitis Optica Spectrum Disorder (NMOSD): Disease Background and Overview

6. Patient Journey

7. Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment and Management

8.2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Neuromyelitis Optica Spectrum Disorder (NMOSD): Seven Major Market Analysis

13.1. Key Findings

13.2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size in 7MM

13.3. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Neuromyelitis Optica Spectrum Disorder (NMOSD) market
To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) market
To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder (NMOSD) market

Related Reports:-

1. Neuromyelitis Optica Market Insight, Epidemiology and Market Forecast -2030

2. Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast to 2030

Hi-Tek Media/Omni Veil Inc. Partners with ISIGN Media for Safety Alert Messaging (“SAM”) Solution to Provide the Public with Instant Mobile Alerts for COVID-19 at No Charge

Las Vegas, NV - Mar 31, 2020 - Hi-Tek Media/Omni Veil Inc. has partnered with iSIGN Media Solutions Inc. (TSX-V: ISD) (OTC: ISDSF), to announce the offer of free use of iSIGN’s Safety Alert Messaging (“SAM”) solution to all levels of medical, health and emergency responders across the U.S. for the next six months.

The goal of this partnership between Hi-Tek Media/Omni Veil Inc. and iSIGN Media is to help our respective medical services, governments, schools and communities combat the spread of COVID-19 and aid in the return of normalcy to everyday life as swiftly as possible.

Right before the announcement of U.S. quarantine, Omni Veil Inc. recently launched their digital network, powered by iSIGN, across Las Vegas. The system is Bluetooth, WiFi and APP based, allowing access to any visitor under the veil no matter their mobile device. The mobile machine provides branded content, video, web link and text notifications. “We want to be sure to do our part to help keep everyone safe. We will get through this, together. We want to keep everyone connected in real time. Our partnership with ISIGN is an excellent resource for the people.” Said Omni Veil President, Michele Bedwell.

We believe that SAM is a tool that would be of interest to newspapers, radio and television stations to expand their reach in the reporting on COVID-19.

SAM is a technology based mobile messaging system that enables the controlled broadcast of critical information to registered recipients. Registered recipients can be as broad as the general public, or as narrow as salaried and contract employees and can be assigned into various sub-groups, allowing for messages to be directed only to specific groups or to everyone, depending on needs. Due to SAM’s ‘message received’ alert function, SAM messages are more obvious to recipients when they are received than texts and email.

As an example, should a hospital administrator want to message individual groups of workers, such as doctors, nurses, cleaning staff, etc., iSIGN’s backend dashboard can be used to assign all registrants into their respective groups. Then the administrator would simple select who they wished the message to be sent to – one group, multiple groups or all groups. SAM supports iOS and Android in-app messaging, the SAM app is available in both the Google Play and Apple app stores. Broadcasters log into the SAM dashboard via their web browser, create and then send messages to their registered recipients in a matter of minutes. Sent messages are stored within the dashboard for later reference as required until the sender deletes them.

About Hi-Tek Media

Hi-Tek Media is a full-service digital advertising and marketing company with 21 years of experience in marketing. Hi-Tek is uniquely positioned to provide cutting edge marketing, digital production and media management Hi-Tek is certified with Google and Facebook and the expansion of our Omni Veil Digital Platform will set us apart from our competitors.

For more information, visit: www.Hi-TekMedia.com

About Omni Veil Inc.

The Omni Veil is a 24/7 Digital Network based in Las Vegas, Nevada. The Network sends out instant traffic notifications, safety messages and branded content for all mobile users. The revolution of the mobile machine’s Bluetooth®, Wi-Fi and Application technologies was developed to keep the public notified, consider first responders’ safety and modernize the way businesses advertise in real time.

For more information, visit: www.theomniveil.com

About iSIGN Media

iSIGN (TSX-V: ISD) (OTC: ISDSF), a Canadian company based in Toronto (Richmond Hill), Ontario is a data-focused, software-as-a-service (SaaS) company that is a pioneering leader in the areas of location-based security alert messaging and proximity marketing utilizing Bluetooth® and Wi-Fi connectivity in complete privacy. Creators of the Smart suite of products, a patented interactive proximity marketing technology, iSIGN enables the delivery of messages to mobile devices in proximity, with real-time reporting and analytics on a variety of metrics. 2019 winner of Richmond Hill’s Innovator of the Year award. Partners include IBM, Keyser Retail Solutions, Baylor University, Verizon Wireless, TELUS and Mtrex Network Solutions.

For more information, visit: www.isignmedia.com

Company contacts:

Lacy Ramon
Director of Digital Technology
Hi-Tek Media Creations
lramon@hi-tekmedia.com

Alex Romanov
President
iSIGN Media Solutions Inc.
alex@isignmedia.com

Media Contact
Company Name: Omni Veil Inc.
Contact Person: Lacy Ramon
Email:Send Email
Phone: 702-279-2925
Country: United States
Website: http://theomniveil.com/

Deltec Bank, the Bahamas, says, AI neural networks will positively disrupt banking

Deltec Bank - Artificial Intelligence

Neural Networks and Machine Learning go hand in hand to interpret and observe data sets. The neural network does what can be called “the dirty work” to output accurate predictions to assist with decision making. The concept of Neural Networks is to mirror the human brain and model complex patterns. These patterns can stem from images, text or sound, labeled or unlabelled. Labeled inputs and outputs mean that data translation is structured.

Neural Networks have now been realized as playing an important role in banking operations. Here are the predicted ways neural networks will disrupt the banking industry:

Locate Credit Card Customers – To maintain sustainable revenue, credit cards need to find the ideal customer. Business profits would significantly reduce if customers that obtain a credit card are not using it. Consider revenue being applied through incremental costs to customers using the credit card to purchase products. If customers obtain credit but don’t use it, the business loses revenue. Neural Networks use intelligent analytics to determine the best customer that will guarantee to generate sufficient revenue. Through the analysis of regular credit card customers, understanding behaviors and habits will help find the ideal customer.
Detect Fraud Through Image Recognition – Image recognition is something that neural networks excel at. The neural network architecture is mirrored to the human brain and can analyze features through trained algorithms to understand the characteristics of a particular image. Through these input features, the model is trained to predict the result. Translating this to banking, neural networks can play a key role in performing image recognition to detect fraudulent transactions and locate where that transaction came from. Neural networks learn features from the data processed and are trained to identify the characteristics of the fraudulent person.
Stock Market Forecasts – Before AI came into existence, many predictors attempted to determine stock market direction through statistics and linear regression concepts. These techniques were used based on human prediction. Neural networks are more accurate when forecasting stock market indices. According to Deltec Bank, Bahamas- “Through predictive analytics, neural networks learn off historical data and historical trends to predict the direction of the market through trained variables and hidden layers.”
Loan Application Evaluation – Loan applications can harm a person’s credit score. All credit histories are hard searched for a person can be considered eligible for a loan application. It is standard for loan applications to be submitted. However, The lender’s role is to see the applicant has no financial difficulties. Banks are aiming to reduce the failure rate of loan applications to help maximize returns. Banks are now seeking to use neural networks to support the process of performing due diligence on an applicant. This works through analyzing any previous failed applications and payment trends before deciding. Neural networks may easily do this and, is expected to be more accurate in its decision making.

Deltec Bank - Bahamas says, “Neural networks haven’t entirely come to the fore of artificial intelligence for banking institutions yet. However, its capability to mirror human decisions will only produce many benefits to customer service, decision making, and internal operations.”

To sum up, neural networks are the driver of deep learning algorithms to represent a human brain’s biological neuron network. There are many ways that neural networks can improve banking operations through predictive analytics to output the accurate decision, to better enhance service of customers and streamline processes, cutting out the middleman and reduce waiting time to make a decision. Neural Networks will eventually form a key foundation layer for bankers to improve automation.

Disclaimer: The author of this text, Robin Trehan, has an undergraduate degree in economics, Masters in international business and finance and MBA in electronic business. Trehan is Senior VP at Deltec International www.deltecbank.com. The views, thoughts, and opinions expressed in this text are solely the views of the author, and not necessarily reflecting the views of Deltec International Group, its subsidiaries and/or employees.

About Deltec Bank

Headquartered in The Bahamas, Deltec is an independent financial services group that delivers bespoke solutions to meet clients’ unique needs. The Deltec group of companies includes Deltec Bank & Trust Limited, Deltec Fund Services Limited, and Deltec Investment Advisers Limited, Deltec Securities Ltd. and Long Cay Captive Management.

Media Contact
Company Name: Deltec International Group
Contact Person: Media Manager
Email:Send Email
Phone: 242 302 4100
Country: Bahamas
Website: https://www.deltecbank.com/

Artist Skyler Jackson Releases New Artwork

Artist Skyler Jackson publishes a new series of digital landscape paintings

Artist Skyler Jackson recently released a new series of digital landscape paintings. These paintings are all unique and similar in style. He shows his talent in creating distant mountains and detailed evergreen trees. Skyler Jackson has created a collection dedicated to nature and landscapes. This art collection includes his first few landscape paintings and his new series including the painting Skyline View.

Art of Skyler Jackson has announced the ability for you to sign up and receive emails when artist Skyler Jackson releases new work, offering a wide range of products and evening offering licensing opportunities to companies and businesses looking for new trendy artwork.

Types of licenses that are available include rights managed licenses for advertising, merchandise, publishing, promotional, and packaging.

This licensing feature is what makes Art of Skyler Jackson stand out from the crowd, having the ability to offer multiple licenses, offers the most value to the businesses. This is what most artists lack, the ability too offer a wider spectrum of licensing opportunities.

Stating this is just the beginning of a new and adventurous art career.

Media Contact
Company Name: Art of Skyler Jackson
Contact Person: Skyler Jackson
Email:Send Email
Phone: 6602518099
Country: United States
Website: https://artofskylerjackson.com

Hallux Valgus Pipeline Insights, 2020

DelveInsight

"Hallux Valgus Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hallux Valgus market. A detailed picture of the Hallux Valgus pipeline landscape is provided, which includes the disease overview and Hallux Valgus treatment guidelines.

Albany, US - DelveInsight launched a new report on Hallux Valgus Pipeline Insights, 2020

Some of the key facts of the report:-

The dynamics of Hallux Valgus market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. The launch of emerging therapies is expected during the forecast period of 2020-2030. The pipeline for Hallux Valgus (Bunion) is not very robust with Ipsen being the key player for the indication. Dysport by Ipsen is an injectable form of a botulinum neurotoxin type A, which is under phase II clinical developmental stage for Hallux Valgus. It is a substance derived from Clostridium bacteria producing BoNT-A which inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. It is currently under development for various other indications as well such as Vulvodynia (phase II), PUL spasticity (phase III) Glabellar lines (registered in China). The expected launch of emerging therapy such as abobotulinumtoxinA (Dysport) (Ipsen) is expected to change the treatment landscape of Hallux Valgus (Bunion) in the upcoming years. Ipsen has a patent protection for the treatment protocol of Hallux Valgus until 2038. Dysport has been recently approved in the United Kingdom in January 2020 for symptomatic treatment of upper limb spasticity in children with cerebral palsy. However, Dysport got approved in the United States in September 2019 for the similar indication as well.

Request for sample pages:- https://www.delveinsight.com/sample-request/hallux-valgus-pipeline-insight

Scope of the Report

The Hallux Valgus report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hallux Valgus across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of Hallux Valgus therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed Hallux Valgus research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hallux Valgus.

Report highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Hallux Valgus.
In the coming years, the Hallux Valgus market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence Hallux Valgus R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the Hallux Valgus treatment market. Several potential therapies for Hallux Valgus are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Hallux Valgus market size in the coming years.
Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Hallux Valgus) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Request for sample pages:- :- https://www.delveinsight.com/sample-request/hallux-valgus-pipeline-insight

Table of contents

1. Report Introduction

2. Hallux Valgus

2.1. Overview

2.2. History

2.3. Hallux Valgus Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Hallux Valgus Diagnosis

2.6.1. Diagnostic Guidelines

3. Hallux Valgus Current Treatment Patterns

3.1. Hallux Valgus Treatment Guidelines

4. Hallux Valgus - DelveInsight's Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Hallux Valgus companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Hallux Valgus Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Hallux Valgus Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Hallux Valgus Late Stage Products (Phase-III)

7. Hallux Valgus Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hallux Valgus Discontinued Products

13. Hallux Valgus Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report?

14. Hallux Valgus Key Companies

15. Hallux Valgus Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Hallux Valgus Unmet Needs

18. Hallux Valgus Future Perspectives

19. Hallux Valgus Analyst Review

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Related reports :-

Hallux Valgus Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Hallux Valgus Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of disease and in depth understanding of disease epidemiology.

Hallux Valgus - Epidemiology Forecast to 2030

DelveInsight's Hallux Valgus - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hallux Valgus in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.